Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.68 |
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | BACE1 | P56817 | 4/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748615 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29602993 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL2980529 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL27914476 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL8821940 | 0.97 | NAALAD2 (0.64) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29827935 | 0.96 | NAALAD2 (0.67) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL29469738 | 0.95 | NAALAD2 (0.61) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL29603574 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1BACE2 | |
| Trifluoroacetic Acid SCHEMBL29617362 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29531169 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| CN-114373510-B | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023083197-A1 | METABOLIC MARKER FOR DIAGNOSING OR MONITORING LUNG CANCER, AND SCREENING METHOD THEREFOR AND USE THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-05-19 | — | — | WO | claimed |
| CN-112964807-B | Metabolism marker for prognosis of chronic acute liver failure of hepatitis B and screening method thereof | 浙江大学 | 2022-09-23 | — | — | CN | claimed |
| CN-114373510-A | Metabolic marker for lung cancer diagnosis or monitoring and screening method and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-113546068-A | A plurality of new components capable of inhibiting enterokinesia in rhizoma Zingiberis recens and its determination method | 山东中医药大学 | 2021-10-26 | — | — | CN | claimed |
| CN-112964807-A | Metabolism marker for prognosis of chronic acute liver failure of hepatitis B and screening method thereof | 浙江大学 | 2021-06-15 | — | — | CN | claimed |
| EP-3554263-A1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | Société des Produits Nestlé S.A. (CH) | 2019-10-23 | — | — | EP | claimed |
| US-20190120855-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | THE CLEVELAND CLINIC FOUNDATION | 2019-04-25 | — | — | US | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| CN-107076753-A | Obese people specific biological marking composition and application thereof | 深圳华大基因科技有限公司 | 2017-08-18 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| US-20150377910-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2015-12-31 | — | — | US | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |